| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 04/16/2009 | WO2009046833A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046832A2 Short peptides used in medicine |
| 04/16/2009 | WO2009046831A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046830A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046829A2 Casoxin d as a therapeutic agent |
| 04/16/2009 | WO2009046827A2 Use of growth hormone-releasing factor and/or mage-3 antigen (271-279) as therapeutic agents |
| 04/16/2009 | WO2009046825A1 Use of a peptide acetyl-calpastatin as a therapeutic agent |
| 04/16/2009 | WO2009046824A2 Use of apelin-12 as a therapeutic agent, eg for treating excessive angiogenesis |
| 04/16/2009 | WO2009046823A1 Exendin-3 and apelin-12 for therapeutic applications |
| 04/16/2009 | WO2009046822A2 Use of the peptide ymdgtmsqv as a therapeutic agent |
| 04/16/2009 | WO2009046802A1 N- ( pyrazole- 3 -yl) -benzamide derivatives as glucokinase activators |
| 04/16/2009 | WO2009046784A1 Pyridine derivatives useful as glucokinase activators |
| 04/16/2009 | WO2009046580A1 The application of the combination of insulin or oral hypoglycemic medicine with raceanisodamine hydrochloride, vitamin b12 and nerve growth factor in the preparation of medicine for treating type ii diabetes |
| 04/16/2009 | WO2009046495A1 A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1 |
| 04/16/2009 | WO2008148849A3 Piperidine/piperazine derivatives |
| 04/16/2009 | WO2008130630A4 Polymorphic form of rimonabant hydrochloride and processes for preparation thereof |
| 04/16/2009 | WO2008011453A3 SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 |
| 04/16/2009 | WO2007011702A3 Use of egfr inhibitors to prevent or treat obesity |
| 04/16/2009 | WO2005042727A3 Methods of organ regeneration |
| 04/16/2009 | US20090099373 Compositions enriched in anthocyanins |
| 04/16/2009 | US20090099265 Trans-clomiphene for metabolic syndrome |
| 04/16/2009 | US20090099259 Method for regulating gene expression |
| 04/16/2009 | US20090099241 Pharmaceutical composition containing antihypertensive agents |
| 04/16/2009 | US20090099240 Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity |
| 04/16/2009 | US20090099238 Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment |
| 04/16/2009 | US20090099230 Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 04/16/2009 | US20090099215 Metabolic enhancing properties of norphenephrine and its salts |
| 04/16/2009 | US20090099208 Novel guanidine derivatives and their medical use |
| 04/16/2009 | US20090099201 Diacylglycerol Acyltransferase Inhibitors |
| 04/16/2009 | US20090099185 P38 Map Kinase Inhibitors |
| 04/16/2009 | US20090099184 Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| 04/16/2009 | US20090099182 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 04/16/2009 | US20090099181 Sulfoximines as kinase inhibitors |
| 04/16/2009 | US20090099180 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 04/16/2009 | US20090099170 Sirtuin modulating compounds |
| 04/16/2009 | US20090099163 Glucokinase activators |
| 04/16/2009 | US20090099155 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| 04/16/2009 | US20090099146 Compositions Containing Sterol-derived Esters |
| 04/16/2009 | US20090099141 Compositions and methods for treating vitamin d deficiencies |
| 04/16/2009 | US20090099105 Content dependent inhibitors of cytidine deaminases and uses thereof |
| 04/16/2009 | US20090099104 Substituted indazoles-o- glucosides |
| 04/16/2009 | US20090099100 Compositions and methods for treating amyloidosis |
| 04/16/2009 | US20090099099 Isoflavone Glycosides as Peroxisome Proliferator-Activated Receptor-alpha Modulator |
| 04/16/2009 | US20090099074 Modulating food intake |
| 04/16/2009 | US20090099073 Albumin Fusion Proteins |
| 04/16/2009 | US20090098569 Novel PGC-1 Isoforms and Uses Therefor |
| 04/16/2009 | US20090098224 Metabolic enhancing properties of theaflavins and thearubigins |
| 04/16/2009 | US20090098223 Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tea containing the same as active ingredient and method for preparing the natural tea |
| 04/16/2009 | US20090098216 Arsenic therapy for apls-type autoimmune lymph-oproliferative syndrome in mice and humans |
| 04/16/2009 | US20090098130 Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| 04/16/2009 | US20090098108 means of delivering the GLP-1 peptide in a sustained manner; obesity related disorders |
| 04/16/2009 | US20090098096 Agent for correcting stress-inducing neuro-mediator, neuro-endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions |
| 04/16/2009 | DE202008016372U1 Vitamin enthaltende Zusammensetzung Vitamin-containing composition |
| 04/16/2009 | DE102007021403B4 Vollei-Zubereitung Whole egg preparation |
| 04/16/2009 | CA2702339A1 Anti-glycation methods and compositions |
| 04/16/2009 | CA2702265A1 Novel seh inhibitors and their use |
| 04/16/2009 | CA2702181A1 Benzothiazoles as ghrelin receptor modulators |
| 04/16/2009 | CA2702057A1 Rapid acting injectable insulin compositions |
| 04/16/2009 | CA2702045A1 Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine |
| 04/16/2009 | CA2701839A1 N- (pyrazole-3-yl) -benzamide derivatives as glucokinase activators |
| 04/16/2009 | CA2701806A1 Pyridine derivatives useful as glucokinase activators |
| 04/16/2009 | CA2700783A1 Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| 04/16/2009 | CA2699257A1 Cgrp as a therapeutic agent |
| 04/16/2009 | CA2699169A1 Therapeutic uses of intermedin 47 and 53 peptides |
| 04/16/2009 | CA2699168A1 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 04/16/2009 | CA2699163A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2699088A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | CA2699084A1 Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent |
| 04/16/2009 | CA2699083A1 Use of a peptide as a therapeutic agent |
| 04/15/2009 | EP2048235A2 Synthetic Mammalian Alpha-N-Acetylglucosaminidase and Genetic Sequences Encoding Same |
| 04/15/2009 | EP2048229A1 Human artificial chromosome (hac) vector, and human cell pharmaceutical comprising human artificial chromosome (hac) vector |
| 04/15/2009 | EP2048162A1 Novel monoclonal antibody and use of the same |
| 04/15/2009 | EP2048153A1 Substituted spiroketal derivative and use thereof as drug for treating diabetes |
| 04/15/2009 | EP2048152A1 Fused ring spiroketal derivative and use thereof as drug for treating diabetes |
| 04/15/2009 | EP2048150A1 Benzyl phenyl glucopyranoside derivative |
| 04/15/2009 | EP2048145A1 Protein kinase c activity enhancer containing alkyl ether derivative or salt thereof |
| 04/15/2009 | EP2048142A2 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| 04/15/2009 | EP2048138A1 Salt or solvate of 5-methyl-2-(piperazin-1-yl)benzenesulfonic acid |
| 04/15/2009 | EP2048137A1 Benzamide derivatives and their use as glucokinase activating agents. |
| 04/15/2009 | EP2047854A1 Pharmaceutical formulations containing ferrous bisglycinate chelate in combination with sweeteners (acesulfam K, sucralose, sorbitol) for improved palatability |
| 04/15/2009 | EP2047851A1 Drug formulation containing fibrate medicament and process for producing the same |
| 04/15/2009 | EP2047844A2 A method of microencapsulation |
| 04/15/2009 | EP2046834A1 Monoclonal antibodies against stromal derived factor-1 (sdf-1) |
| 04/15/2009 | EP2046791A2 Urea derivatives of tropane, their preparation and their therapeutic application |
| 04/15/2009 | EP2046775A1 N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 04/15/2009 | EP2046753A2 Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors |
| 04/15/2009 | EP2046737A2 2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof |
| 04/15/2009 | EP2046734A1 Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors |
| 04/15/2009 | EP2046722A2 Beta-3 receptor ligands and their use in therapy |
| 04/15/2009 | EP2046716A1 Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof |
| 04/15/2009 | EP2046715A1 Substituted 1,3-diphenylpropane derivatives, preparations and uses thereof |
| 04/15/2009 | EP2046351A2 Adult sertoli cells and uses thereof |
| 04/15/2009 | EP2046346A1 Novel sglt inhibitors |
| 04/15/2009 | EP2046327A1 Medical use of cyclin dependent kinases inhibitors |
| 04/15/2009 | EP2046313A1 The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia |
| 04/15/2009 | EP1945044B1 Compositions for increasing lean muscle mass and/or reducing fat gain |
| 04/15/2009 | EP1680099B1 Hdl-boosting combination therapy complexes |
| 04/15/2009 | EP1663989B1 CRYSTALLINE FORM OF BIS (E)-7- 4-(4-FLUOROPHENYL)-6-IS OPROPYL-2- METHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL&r sqb;(3R,5S)-3,5-DIHYDROXYHEPT-6 -ENOICACID CALCIUM SALT |
| 04/15/2009 | EP1480678B1 Treatment of ophthalmic disorders using urea and urea derivatives |
| 04/15/2009 | EP1458677B1 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha |